VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the preliminary results of a phase Ib study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter